CTI BioPharma (CTIC) 10-K2016 FY Annual report

Filed: 2 Mar 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: absolute, Adam, add, adjuvant, AEs, Allergan, antifraud, arose, assembled, ASU, Bachelor, bad, British, burden, cardiovascular, censored, center, CEO, Charing, Chemgenex, CI, clinician, CMO, collusion, comported, conceived, concurred, confidence, Craig, CTRC, disagreed, disinterested, DMC, durable, duty, eleven, England, excused, explicitly, faulty, Forest, Foundation, Hazard, hemoglobin, Hill, identification, Ignagni, ILEX, immunoconjugate, impartiality, ineligible, inquiry, IRC, Karen, Leadership, led, London, longstanding, mandate, MBA, Mersana, MESA, Metzger, Michael, mismanagement, Molecular, mortality, Nahar, Onconova, OS, override, oversaw, pacritnib, pacrtinib, Pediatric, pharmacokinetic, plaintiff, plc, pneumonia, political, pooled, pound, predisposed, QD, reacquisition, referendum, Regado, renal, reoccurrence, resumed, resumption, Royal, ruxolinitib, School, Shire, simple, sought, statistician, stay, subpoena, Subtopic, SVR, Syndax, team, Telematico, TGen, Tobira, told, travel, Triton, Trump, turnover, unblinded, undertook, unjust, unopposed, upcoming, venture, virtually, Wei, Westminster, wrongful

Removed: Abraxane, accomplish, accumulation, acid, activated, Alimta, analyzed, arise, Australia, Avastin, biodegradable, bloodstream, breast, called, carboplatin, carrier, cathepsin, channel, chemical, chemotherapeutic, circulation, classify, codified, conjugated, cytotoxic, damaged, discounted, diverse, docetaxel, encouraging, enzyme, fundamental, futility, gene, inactive, inform, linked, linking, lung, mezzanine, mutated, passive, penalty, PFS, pivotal, polyglutamate, preferentially, prolonged, prostate, realizing, rebate, resalable, returned, reveal, Russia, site, sparing, specialty, stable, subjected, Tarceva, Taxol, Taxotere, tissue, utilization, yew, Zealand, Zevalin

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CTIC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 12.1

RATIO OF EARNINGS TO FIXED CHARGES

The following table sets forth our ratio of earnings to fixed charges for each of the periods indicated:



	Year ended December 31,
	2016	2015	2014	2013	2012
Ratio of earnings to fixed charges (1)	—	—	—	—	—

(1) Earnings were not sufficient to cover fixed charges for each of the periods indicated. Earnings consist of income (loss) before provision for income taxes plus fixed charges less income (loss) attributable to noncontrolling interest. Fixed charges consist of interest charges, amortization of debt expense and discount related to indebtedness, and that portion of rental payments under operating leases we believe to be representative of interest. Earnings for the years ended December 31, 2016, 2015, 2014, 2013 and 2012, were insufficient to cover fixed charges by $52.0, $122.6, $96.0, $49.6 and $115.3 (in millions), respectively. For this reason, no ratios are provided for these periods.